Development of five new melanoma low passage cell lines representing the clinical and genetic profile of their tumors of origin

Pigment Cell and Melanoma Research

Volumn 25, Issue 3, 2012, Pages 395-397

  de Miera, Eleazar Vega Saenz ^a   Friedman, Erica B ^a   Greenwald, Holly S ^a   Perle, Mary A ^a   Osman, Iman ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARBOPLATIN; MELAN A; MK 1775; PROTEIN S 100; TEMOZOLOMIDE; UNCLASSIFIED DRUG; B RAF KINASE; BRAF PROTEIN, HUMAN;

CANCER CELL CULTURE; CANCER GROWTH; CANCER RESEARCH; CARCINOGENICITY; CELL GROWTH; GENE EXPRESSION PROFILING; GENETIC DISORDER; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MELANOMA; CANCER OF UNKNOWN PRIMARY SITE; CLASSIFICATION; GENE EXPRESSION REGULATION; GENETICS; METHODOLOGY; MISSENSE MUTATION; PATHOLOGY; PHYSIOLOGY; PRIMARY CELL CULTURE; PROGNOSIS; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TUMOR; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; HUMANS; MELANOMA; MUTATION, MISSENSE; NEOPLASMS, UNKNOWN PRIMARY; POLYMORPHISM, SINGLE NUCLEOTIDE; PRIMARY CELL CULTURE; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RNA SPLICING; SKIN NEOPLASMS;

EID: 84865341936     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2012.00994.x     Document Type: Letter

References (10)

1. Albino, A.P., Sozzi, G., Nanus, D.M., Jhanwar, S.C., and Houghton, A.N. (1992). Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene 7, 2315-2321.
2. Becher, R., Gibas, Z., Karakousis, C., and Sandberg, A.A. (1983). Nonrandom chromosome changes in malignant melanoma. Cancer Res. 43, 5010-5016.
3. Hoglund, M., Gisselsson, D., Hansen, G.B., White, V.A., Sall, T., Mitelman, F., and Horsman, D. (2004). Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution. Int J Cancer 108, 57-65.
4. Kameyama, K., Vieira, W.D., Tsukamoto, K., Law, L.W., and Hearing, V.J. (1990). Differentiation and the tumorigenic and metastatic phenotype of murine melanoma cells. Int. J. Cancer 45, 1151-1158.
5. Loo, J.C., Liu, L., Hao, A. et al. (2003). Germline splicing mutations of CDKN2A predispose to melanoma. Oncogene 22, 6387-6394.
6. Rutter, J.L., Goldstein, A.M., Davila, M.R., Tucker, M.A., and Struewing, J.P. (2003). CDKN2A point mutations D153spl(c.457G > T) and IVS2+1G > T result in aberrant splice products affecting both p16(INK4a) and p14(ARF). Oncogene 22, 4444-4448.
7. Salgia, R., and Skarin, A.T. (1998). Molecular abnormalities in lung cancer. J. Clin. Oncol. 16, 1207-1217.
8. Schadendorf, D., Fichtner, I., Makki, A., Alijagic, S., Kupper, M., Mrowietz, U., and Henz, B.M. (1996). Metastatic potential of human melanoma cells in nude mice-characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br. J. Cancer 74, 194-199.
9. Wich, L.G., Hamilton, H.K., Shapiro, R.L. et al. (2009). Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. Am. J. Transl. Res. 1, 35-43.
10. Wiese, C., Rolletschek, A., Kania, G., Blyszczuk, P., Tarasov, K.V., Tarasova, Y., Wersto, R.P., Boheler, K.R., and Wobus, A.M. (2004). Nestin expression - a property of multi-lineage progenitor cells? Cell. Mol. Life Sci. 61, 2510-2522.